A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

September 2, 2026 updated by: Merck Sharp & Dohme LLC

An Open-label, Phase 1 Study to Individually Characterize the Food Effect, the Drug-Drug Interaction Effect of OAT Inhibition, and the Drug-Drug Interaction Effect of P-glycoprotein Inhibition on the Pharmacokinetics of MK-8527 in Healthy Adult Participants

Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults.

The goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
44

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • Florida
      • Daytona Beach, Florida, United States, 32117
        • Fortrea Clinical Research Unit Inc ( Site 0001)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Be in good health
  • Has a body mass index (BMI) between 18 and 32 kg/m^2, inclusive

Exclusion Criteria:

  • Has an estimated glomerular filtration rate (eGFR) ≤90 mL/min/1.73 m^2
  • Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)
  • Has a history of cancer (malignancy)
  • Is taking any medication that contains emtricitabine (FTC) or lamivudine (3TC)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Part 1: MK-8527
Participants will receive a single dose of MK-8527 with food and a single dose of MK-8527 without food.
Drug: MK-8527
Oral tablet
Experimental: Part 2: MK-8527 + Probenecid
Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with probenecid.
Drug: MK-8527
Oral tablet
Drug: Probenecid
Oral tablet
Experimental: Part 3: MK-8527 + Itraconazole
Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with itraconazole.
Drug: Itraconazole
Oral solution
Drug: MK-8527
Oral tablet

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Part 1: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma With and Without Food
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 2: AUC0-inf of MK-8527 in Plasma With and Without Probenecid
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 3: AUC0-inf of MK-8527 in Plasma With and Without Itraconazole
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Part 1: Area Under the Concentration Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-8527 in Plasma With and Without Food
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected at multiple time points to estimate AUC0-336 of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-8527 in Plasma With and Without Food
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the Tmax of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 1: Maximum Plasma Concentration (Cmax) of MK-8527 in Plasma With and Without Food
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the Cmax of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 1: Apparent Terminal Half-life (t1/2) of MK-8527 in Plasma With and Without Food
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the apparent terminal t1/2 of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 1: Number of Participants Who Experience an Adverse Event (AE)
Time Frame: Up to approximately 43 days
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience AE will be reported.
Up to approximately 43 days
Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE
Time Frame: Up to approximately 43 days
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Up to approximately 43 days
Part 2: AUC0-336 of MK-8527 in Plasma With and Without Probenecid
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the AUC0-336 of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 2: Tmax of MK-8527 in Plasma with and without Probenecid
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the Tmax of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 2: Cmax of MK-8527 in Plasma With and Without Probenecid
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the Cmax of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 2: Apparent Terminal t1/2 of MK-8527 in Plasma With and Without Probenecid
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the apparent terminal t1/2 of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 2: Urine Concentration at 72 Hours of MK-8527
Time Frame: At designated timepoints (up to 72 hours postdose)
Urine samples will be collected to estimate the urine concentration of MK-8527.
At designated timepoints (up to 72 hours postdose)
Part 2: Renal Clearance of MK-8527
Time Frame: At designated timepoints (up to 72 hours postdose)
Urine samples will be collected to estimate the renal clearance of MK-8527.
At designated timepoints (up to 72 hours postdose)
Part 2: Number of Participants Who Experience an AE
Time Frame: Up to approximately 43 days
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience AE will be reported.
Up to approximately 43 days
Part 2: Number of Participants Who Discontinue Study Treatment Due to an AE
Time Frame: Up to approximately 43 days
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Up to approximately 43 days
Part 3: AUC0-336 of MK-8527 in Plasma With and Without Itraconazole
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected at multiple time points to estimate AUC0-336 of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 3: Tmax of MK-8527 in Plasma With and Without Itraconazole
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the Tmax of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 3: Cmax of MK-8527 in Plasma With and Without Itraconazole
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the Cmax of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 3: Apparent Terminal t1/2 of MK-8527 in Plasma With and Without Itraconazole
Time Frame: Predose and at designated timepoints (up to 336 hours postdose)
Blood samples will be collected to estimate the apparent t1/2 of MK-8527 in plasma.
Predose and at designated timepoints (up to 336 hours postdose)
Part 3: Urine Concentration at 72 Hours of MK-8527
Time Frame: At designated timepoints (up to 72 hours postdose)
Urine samples will be collected to estimate the urine concentration of MK-8527.
At designated timepoints (up to 72 hours postdose)
Part 3: Renal Clearance of MK-8527
Time Frame: At designated timepoints (up to 72 hours postdose)
Urine samples will be collected to estimate the renal clearance of MK-8527.
At designated timepoints (up to 72 hours postdose)
Part 3: Number of Participants Who Experience an AE
Time Frame: Up to approximately 43 days
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience AE will be reported.
Up to approximately 43 days
Part 3: Number of Participants Who Discontinue Study Treatment Due to an AE
Time Frame: Up to approximately 43 days
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Up to approximately 43 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Merck Sharp & Dohme LLC

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Medical Director, Merck Sharp & Dohme LLC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 30, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 9, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 9, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 16, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 8527-021
  • MK-8527-021 (Other Identifier: MSD)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings